Table 3.
Comparison of demographic and clinical characteristics of 368 patients with RCC included in the ReLife study and 468 invited non-participants
| Participants | Non-participants | P value* | |
| N | 368 | 468 | |
| Age category (years) | |||
| 18–44 | 14 (4) | 28 (6) | 0.34 |
| 45–64 | 180 (49) | 218 (47) | |
| 65–75 | 174 (47) | 222 (47) | |
| Sex | |||
| Male | 257 (70) | 360 (77) | 0.02 |
| Female | 111 (30) | 108 (23) | |
| Tumour stage | |||
| I | 238 (65) | 298 (64) | 0.51 |
| II | 55 (15) | 61 (13) | |
| III | 75 (20) | 109 (23) | |
| Fuhrman grade | |||
| 1 | 49 (13) | 86 (18) | 0.32 |
| 2 | 185 (50) | 219 (47) | |
| 3 | 67 (18) | 74 (16) | |
| 4 | 23 (6) | 33 (7) | |
| Unknown | 44 (12) | 56 (12) | |
| Morphology | 0.97 | ||
| Clear cell renal tumour | 260 (71) | 338 (72) | |
| Papillary renal tumour | 48 (13) | 58 (12) | |
| Chromophobe renal tumour | 25 (7) | 30 (6) | |
| Other† | 35 (9) | 42 (9) | |
| Treatment | |||
| Radical nephrectomy | 210 (57) | 272 (58) | 0.76 |
| Partial nephrectomy | 152 (41) | 191 (41) | |
| Ablation‡ | 6 (2) | 5 (1) |
Values are n (%).
*From χ2 test.
†Other morphology consists of adenocarcinoma with mixed subtypes (n=4 and n=5), eosinophilic solid and cystic renal cell carcinoma (n=1 and n=0), renal cell carcinoma not otherwise specified (n=28 and n=29), sarcomatoid renal cell carcinoma (n=2 and n=6), collecting duct carcinoma (n=0 and n=1) and clear cell papillary renal cell tumour (n=0 and n=1) for participants and non-participants, respectively.
‡Other treatment consists of cryoablation (n=2 and n=2), radiofrequency ablation (n=3 and n=2) and microwave ablation (n=1 and n=1) for participants and non-participants, respectively.
RCC, renal cell cancer; ReLife, Renal cell cancer: Lifestyle, prognosis and quality of life.